BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Exploit Technologies Portfolio Companies Performed Well to Secure S$500,000 Grant under SPRING Singapore's Technology Enterprise Commercialisation Scheme (TECS)


6/4/2009 3:14:08 PM

Singapore, 4 June 2009 – SPRING Singapore today announced that the second batch of technology start-ups has won the second competitive grant under the Technology Enterprise Commercialisation Scheme (TECS). A group of four portfolio companies under Exploit Technologies, namely, Curiox Biosystems Pte Ltd, D-SIMLAB Technologies Pte Ltd, Niometrics Pte Ltd and SG Molecular Diagnostics Pte Ltd, were each awarded up to S$500,000 under TECS for their Proof-Of-Value Projects. There were 13 winners in the Proof-Of-Value category.

TECS is a competitive grant and evaluated by investment professionals and industry leaders. Only the strongest proposals with the best potential commercial outcome are funded. The second batch of winners was evaluated on the commercial potential, scientific and technical strengths, cost-effectiveness and impact of their projects. A total of 21 new winners were selected from 220 submissions. Of the 21 start-ups, eight of them involved projects at the Proof-of-Concept (POC) stage, while the remaining 13 were at the Proof-of-Value (POV) stage.

Commenting on the successful feat by Exploit Technologies’ portfolio companies, Mr Boon Swan Foo, Executive Chairman of Exploit Technologies said, “To clinch the TECS Award, after competing against more than 200 applicants, is already an endorsement of these companies’ technical strengths and marketing and development capabilities; to have four companies that made the mark, out of pool of only 13 winners, is a strong testimony to A*STAR technologies and Exploit Technologies’ efforts in nurturing these companies.

“Exploit Technologies has worked very closely with these four teams in the early days of their business all the way through the TECS application. Experienced teams, with extensive industry and start-up experience, have helped to shape the start-ups’ business plans, advise them on the product development roadmaps, open up doors to business leads, mentor them on the various aspects of starting a business, find funding through venture capitalists and angel investors, as well as prepare the founders for elevated pitches. We believe that in helping A*STAR’s start-ups to secure TECS Grant and other sources of funding, Exploit Technologies is developing a multi-pathway approach to commercialisation. This will go a long way in bringing to the market more of such promising technologies and companies.”

The founders of all four companies were either researchers with the Singapore Agency for Science, Technology and Research’s (A*STAR) research institutes or have leveraged A*STAR technologies in their businesses. Curiox Biosystems Pte Ltd was spun off in 2007 from A*STAR Institute of Bioengineering Nanotechnology (IBN), DSIMLAB Technologies Pte Ltd in 2006 from Singapore Institute of Manufacturing Technology (SIMTech) and Niometrics Pte Ltd is a potential spin-off from the Institute for Infocomm Research (I2R). SG Molecular Diagnostics Pte Ltd took a licence from Exploit Technologies

Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES